Loading
companiesCompany
Sichuan Kelun-Biotech
Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.
Overview
Sichuan Kelun-Biotech, based in Chengdu and listed in Hong Kong as 6990.HK, is the Chinese antibody-drug conjugate developer whose TROP2 ADC sacituzumab tirumotecan, or sac-TMT, was licensed to Merck in one of the largest China-out deals, worth up to 9.3 billion dollars. Sac-TMT was the first TROP2 ADC approved in China, MK-3120 is its Nectin-4 ADC, and a broad ADC platform sits behind the Merck partnership, with Binghe Xu among the investigators linked. OnCo connects it to triple-negative breast cancer, to the TROP2 ADC roadmap that runs from sacituzumab govitecan through datopotamab deruxtecan to sac-TMT, to Sichuan Cancer Hospital and to the NMPA. Whether sac-TMT can repeat its Chinese results in Western trials is the open question. Sacituzumab tirumotecan has its own page.
Headquarters
Chengdu, CN
Scorecard
All companies#98of 1244 companies, score 51
- approved products +6
- phase 3 +6
- phase 1/2 +1
- targets +4
- modalities +4
- regions +1
- 24-month regulatory events +8
- registry trials +21
1 approved, 2 in phase 3, 1 earlier, 2 targets, 114 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2022-12 | Sichuan Kelun-Biotech to Merck & Co. (MSD) Up to seven preclinical ADCs | Licence | $175m | up to $9.3bn | source |
| 2022-05 | Sichuan Kelun-Biotech to Merck & Co. (MSD) Sacituzumab tirumotecan (SKB264, MK-2870), TROP2 ADC | Licence | $47m | up to $1.4bn | source |
Type
Biotech · 6990.HK
Stage
Public
Website
ApprovedADC
Sacituzumab tirumotecan is Kelun-Biotech's TROP2 ADC, approved in China in 2024 for pretreated triple-negative breast cancer and then EGFR-mutant lung cancer. Merck holds rights outside Greater China and runs the TroFuse programme of more than ten phase 3 trials across breast, lung, endometrial and cervical cancer; in the US it holds a priority voucher but no approval yet.
Phase 3monoclonal antibody (KL-A167 is tagitanlimab; INN stem -mab; form not stated in the registry record)
KL-A167 is an experimental investigational agent whose form is not stated in the registry from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for nasopharyngeal carcinoma and non-small-cell lung cancer, with its target not yet stated publicly.
Phase 3ADC
A166 is an experimental antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for HER2-positive breast cancer, aimed at HER2.
Phase 2Antibody-drug conjugate
SKB105 is an antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., in registered phase 2 trials for metastatic cancer.
cancers
fronts
drugs
Phase 3ADC
Phase 3monoclonal antibody (KL-A167 is tagitanlimab; INN stem -mab; form not stated in the registry record)
ApprovedADC
Phase 2Antibody-drug conjugate
institutions
trials
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or MetastatiA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET AbnormalitiesA Phase II Study of SKB571 in Patients With Lung CancerA Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsA Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerA Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyA Study of KL590586 in Patients With Advanced Solid TumorsA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally AdvanA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative PA Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyA Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant TumorsA Study of SKB518 in Patients With Lung CancerA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaPhase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth FactoSacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesSKB103 for Injection in Advanced Solid TumorsSKB105 for Injection in Advanced Solid TumorsSKB118 Injection in Advanced Solid TumorsSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsSKB264 in Combination With SKB118 for Non-Small Cell Lung CancerSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerSKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsSKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaSKB500 Combinations in Patients With Small Cell Lung CancerSKB565 for Injection in Advanced Solid TumorsStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerStudy to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OCToripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC